NZP at NZBio 2012
NZP’s CEO, Andy Lewis, will be a plenary speaker at the NZ Bio conference on Tuesday 27 March 2012, www.nzbio2012.co.nz to discuss the development of NZP’s new drug candidate, DEX-M74 to treat Hereditary Inclusion Body Myopathy (HIBM). HIBM is a rare, adult onset, limb muscle wasting disease.
This is NZP’s first drug development project for a rare disorder and it is being developed with support from the U.S. National Institutes of Health. NZP licenced the Intellectual Property from the NIH’s National Human Genome Research Institute (NHGRI) and this Plenary will be about the relationship with the teams from the NIH, who cover the discovery, intellectual property management and project support from Therapeutics for Rare and Neglected Disease department (TRND) of the National Center for Advancing Translational Sciences (NCATS) of the NIH.
John Shen, Program Manager for TRND and especially the HIBM project will also be on stage. John will share the benefits of working with the TRND team and use NZP as a case study. Andy believes that the NIH and TRND offers excellent opportunities for NZ based drug development and biotech companies to work with the NIH and it is clearly noted that the NIH will work with any suitable team around the world.
New Zealand's MSI has assisted with R&D support (TechNZ) and NZTE (IGF) with travel support to the USA.